CAS 119911-68-1
:calcitonin gene related peptide*fragment 8-37 hum
Description:
Calcitonin gene-related peptide (CGRP) fragment 8-37 is a peptide that serves as a potent antagonist of CGRP receptors. It is derived from the CGRP molecule, which plays a significant role in various physiological processes, including vasodilation and pain transmission. The fragment 8-37 specifically refers to a portion of the CGRP sequence, which has been modified to inhibit the activity of the full-length peptide. This antagonist is particularly relevant in research related to migraine pathophysiology, as CGRP is implicated in migraine attacks. The CAS number 119911-68-1 identifies this specific peptide fragment in chemical databases, facilitating its use in scientific studies and pharmaceutical applications. In terms of characteristics, CGRP fragment 8-37 is typically characterized by its peptide structure, which includes a sequence of amino acids that confer its biological activity. It is often synthesized for research purposes and may be used in various experimental settings to explore its effects on CGRP signaling pathways and related physiological responses.
Formula:C139H230N44O38
InChI:InChI=1S/C139H230N44O38/c1-66(2)48-86(161-102(193)60-155-113(197)74(17)159-120(204)87(49-67(3)4)168-118(202)83(40-31-45-152-138(147)148)163-123(207)90(53-80-57-151-65-158-80)173-136(220)111(77(20)188)182-131(215)105(145)69(7)8)121(205)169-88(50-68(5)6)122(206)176-96(64-186)129(213)165-84(41-32-46-153-139(149)150)119(203)175-94(62-184)115(199)156-58-101(192)154-59-104(195)177-107(71(11)12)134(218)179-108(72(13)14)133(217)166-82(39-28-30-44-141)117(201)171-91(54-98(142)189)125(209)172-92(55-99(143)190)124(208)170-89(52-79-36-25-22-26-37-79)126(210)180-109(73(15)16)137(221)183-47-33-42-97(183)130(214)181-110(76(19)187)135(219)174-93(56-100(144)191)127(211)178-106(70(9)10)132(216)157-61-103(194)162-95(63-185)128(212)164-81(38-27-29-43-140)116(200)160-75(18)114(198)167-85(112(146)196)51-78-34-23-21-24-35-78/h21-26,34-37,57,65-77,81-97,105-111,184-188H,27-33,38-56,58-64,140-141,145H2,1-20H3,(H2,142,189)(H2,143,190)(H2,144,191)(H2,146,196)(H,151,158)(H,154,192)(H,155,197)(H,156,199)(H,157,216)(H,159,204)(H,160,200)(H,161,193)(H,162,194)(H,163,207)(H,164,212)(H,165,213)(H,166,217)(H,167,198)(H,168,202)(H,169,205)(H,170,208)(H,171,201)(H,172,209)(H,173,220)(H,174,219)(H,175,203)(H,176,206)(H,177,195)(H,178,211)(H,179,218)(H,180,210)(H,181,214)(H,182,215)(H4,147,148,152)(H4,149,150,153)/t74-,75-,76+,77+,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,105-,106-,107-,108-,109-,110-,111-/m0/s1
InChI key:NDACAFBDTQIYCQ-YVQXRMNASA-N
SMILES:C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N)O
Synonyms:- Calcitonin Gene-Related Peptide-I 8-37, Human
- .alpha.-CGRP (8-37) (human)
- H-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
α-CGRP (8-37) (human)
CAS:CGRP and calcitonin cross-react with each other at the levels of their distinct receptors. α-CGRP (8-37) has been described as a selective antagonist for CGRP receptors but not for calcitonin receptors. This fragment thus appears to be a valuable tool for receptor characterization studies.Formula:C139H230N44O38Purity:97.8%Color and Shape:White LyophilisateMolecular weight:3125.63HCGRP-(8-37)
CAS:Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective CGRP receptor antagonistFormula:C139H230N44O38Purity:98%Color and Shape:SolidMolecular weight:3125.59(S)-2-((2S,3R)-2-((S)-1-(L-Valyl-L-threonyl-L-histidyl-L-arginyl-L-leucyl-L-alanylglycyl-L-leucyl-L-leucyl-L-seryl-L-arginyl-L-serylglycylglycyl-L-valyl-L-valyl-L-lysyl-L-asparaginyl-L-asparaginyl-L-phenylalanyl-L-valyl)pyrrolidine-2-carboxamido)-3-hydroxybutanamido)-N1-((S)-1-(((4S,7S,10S,13S)-7-(4-aminobutyl)-13-carbamoyl-4-(hydroxymethyl)-10-methyl-2,5,8,11-tetraoxo-14-phenyl-3,6,9,12-tetraazatetradecyl)amino)-3-methyl-1-oxobutan-2-yl)succinamide
CAS:Formula:C139H230N44O38Purity:98%Molecular weight:3125.59CGRP (Human, 8-37)
CAS:CGRP (Human, 8-37) is a peptide derived from the calcitonin gene-related peptide (CGRP) that is found in the nervous system and other tissues in humans. It is a truncated form of the full-length CGRP peptide, consisting of the last 30 amino acids of the CGRP sequence (amino acids 8-37).
CGRP is a potent vasodilator and plays a key role in regulating blood flow and blood pressure. It is also involved in pain perception, inflammation, and neurogenic inflammation. CGRP (Human, 8-37) is an antagonist of CGRP, meaning that it binds to the CGRP receptor without activating it, thereby blocking the effects of CGRP.
CGRP (Human, 8-37) has been used as a research tool to study the physiological and pathological roles of CGRP in various tissues and diseases, such as migraine headaches, cardiovascular diseases, and inflammatory disorders. It has also been investigated as a potential therapeutic agent for these conditions, as well as for the treatment of pain and other neurological disorders.
This product is available as a 0.5mg vial.Formula:C139H230N44O38Purity:Min. 95%Molecular weight:3,125.6 g/molα-CGRP (8-37) (HUMAN)
CAS:Formula:C139H230N44O38Purity:97%Color and Shape:SolidMolecular weight:3125.5855
